Cancer Therapeutics Market

Cancer Therapeutics Market Analysis Report By Top Selling Drugs (Revlimid, Avastin, Herceptin, Rituxan), By Application (Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer), By End-User, By Region - Global Insights 2022 to 2032

Analysis of Cancer Therapeutics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Global Cancer Therapeutics Market Outlook

The global cancer therapeutics market is estimated at USD 12.1 Billion in 2022 and is forecast to surpass USD 28.3 Billion by 2032, growing at a CAGR of 8.8% from 2022 to 2032.

Report Attributes


Base Year Value (2021A)

USD 11.2 Billion

Estimated Year Value (2022E)

USD 12.1 Billion

Projected Year Value (2032F)

USD 28.3 Billion

Global Growth Rate (2022-2032)

 CAGR 8.8%

North America Market Share in 2021


North America Growth Rate (2022-2032)

CAGR ~9.1%

Collective Value Share (US, China, India) 2022: Top 3 Countries


Top 5 Companies Market Share in 2021


Key Companies Profiled

  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Novartis AG
  • Johnson and Johnson
  • GlaxoSmithKline Plc
  • Other Market Players

The global cancer therapeutics market is likely to create an absolute dollar opportunity of USD 16.2 Billion by the end of 2032. The global cancer therapeutics market holds ~12% of the global therapeutics market.

2017-2021 Global Cancer Therapeutics Market Outlook in Comparison to 2022-2032 Growth Forecast

Causing over 8 million deaths in 2015, the global burden of cancer incidence is still on the rise. Considering the biological diversity of cancer and declining therapeutic values of conventional cancer treatments due to drug resistance, a wide range of new cancer therapies are being developed.

Though a majority of existing cancer treatments involve surgical procedures to remove tumor mass, novel delivery approaches to cancer therapeutics are triggering the emergence of new treatment modalities such as peptide-based therapies and peptide-based drugs in the cancer care landscape.

The efficacy of peptide-based therapies became well known to the healthcare industry with advent of insulin therapy, and peptide-based drug delivery was introduced to the cancer therapeutics market.

Implementation of peptide drugs and peptide therapies in cancer therapeutics landscape has evolved remarkably in the past few years, and incorporating peptide-based drugs in chemotherapy has become a promising way to improve efficacy of cancer treatment today.

Stakeholders in the cancer therapeutics market are bolstering research into novel delivery approached that include combining peptide vaccines, peptide-based drugs, peptide-based therapies, and peptide-conjugated nanomaterials in cancer care to introduce innovative and more efficient cancer treatments.

Furthermore, with the ongoing research and clinical studies in personalized medicines for combating cancer, a new window of opportunities is likely to open for peptide-based drugs and peptide-based therapies in the cancer therapeutics market.

Fact.MR projects the cancer therapeutics market is expected to witness exhibiting growth at 8.8% CAGR during 2022 and 2032 in comparison to a CAGR of 6.4% with which it grew from 2017 and 2021.

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Improving Profitability and Efficacy of Peptide-based Therapies in Cancer Treatment

With the cancer therapeutics industry being steadfast in its research & development (R&D) activities, discoveries of innovative peptide-based drugs are expected to influence the emerging trends in the peptide-based cancer therapeutics market.

Adoption of peptide-based drugs in cancer treatments is expected to pick pace in the coming years, and growing awareness about unique benefits of peptide-based therapies in physical and non-surgical cancer treatments is mainly attributed for this trend.

As the genomic era in the healthcare industry allows healthcare professionals to identify and characterize endogenous peptide hormones for their receptors, and this has been encouraging healthcare professionals and researchers to kickstart development of novel peptide ligands targeting these receptors.

Cell-penetrating peptides are emerging as a highly efficient ligand incorporated in peptide-based therapeutics not only for conventional but also for oligonucleotide-based cancer therapeutics. Such innovations in the ligand or receptor-based targeting approaches are expected to foster growth of peptide-based therapies and peptide-based drugs in cancer therapeutics in the coming years.

Bortezomib: A Peptide-based Drug in Cancer Treatment for Inhibiting Proteasome

The global market for cancer therapeutics has been advancing with the recent discoveries of novel peptide-based drugs that can further enhance the efficacy of existing treatments. The hunt for natural and synthetic proteasome inhibitors is fueling research and development activities in the landscape, which is expected to transform peptide-based therapies in the cancer therapeutics market. In the coming years, the demand for peptide-based drugs that can target the ubiquitin-proteasome pathway is expected to give rise to new trends in the market.

The adoption of bortezomib as a peptide-based drug is increasing in chemotherapeutic drug in treatments for various cancers including colon cancer, ovarian cancer, prostate cancer, and hepatocellular carcinoma.

As bortezomib enables boosting the cellular susceptibility of cancers to apoptosis, its adoption in peptide-based therapies in cancer treatments is expected to increase. Furthermore, the peptide-based drug also prohibits proteasome, which is primarily why it is becoming an integral part of peptide-based therapies for multiple myeloma.

Bortezomib is also gaining immense popularity owing to its contribution as a peptide-based drug in enhancing disease management services in cancer therapeutics, resulting in increased lifespan of patients. This is likely to make peptide-based drugs, including bortezomib, an indispensable part of the future of cancer therapeutics.

With the growing awareness about the immense potential for peptide-based therapies in cancer treatments, leading stakeholders are expected to increasing investments in the R&D to discovery novel peptide-based drugs to gain a competitive edge in the cancer therapeutics market.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Competitive Landscape: Top Companies in Cancer Therapeutics Market

The global cancer therapeutics market is highly fragmented and competitive owing to the existence of many domestic and regional players. Various marketing strategies are adopted by key players such as mergers and acquisitions, expansions, collaborations and partnerships.

Also, new product development as a strategic approach is adopted by the leading companies to upscale their market presence among consumers. These strategies have resulted in the growth of cancer therapeutics.

Fact.MR has provided detailed information about price points of key manufacturers in cancer therapeutics market positioned across regions, sales growth, production capacity, and speculative technological expansion in the recently published report.

For instance:

  • AstraZeneca in 2021 announced the acquisition of Alexion Pharmaceuticals, Inc. This will allow the company to mark an entry into medicines for rare diseases
  • Pfizer Inc. in 2021 announced the acquisition of Arena Pharmaceuticals. This acquisition will address the needs for patients with immune-inflammatory diseases

Global Cancer Therapeutics Market by Category

  • By Top Selling Drugs, Global Cancer Therapeutics Market is segmented as:

    • Revlimid
    • Avastin
    • Herceptin
    • Rituxan
    • Opdivo
    • Others
  • By Application, Global Cancer Therapeutics Market is segmented as:

    • Blood Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Breast Cancer
    • Others
  • By End-User, Global Cancer Therapeutics Market is segmented as:

    • Hospitals
    • Specialty Clinics
    • Cancer and Radiation Therapy Centers
  • By Region, Global Cancer Therapeutics Market is segmented as:

    • North America
    • Latin America
    • Europe
    • East Asia
    • South Asia & Oceania
    • MEA

- FAQs -

What is the global Cancer Therapeutics Market scenario?

The global value of cancer therapeutics market is estimated to be worth over USD 12.1 Billion in 2022.

How far is the global demand expected to reach over the forecasted period?

The demand is anticipated to surpass USD 28.3 Billion by 2032 end.

What was the last 5-year CAGR for the demand in the Cancer Therapeutics Market?

During 2017-2021, global cancer therapeutics market grew at 6.4% CAGR.

Who are the prominent players in the global Cancer Therapeutics Market?

Some of the prominent players in cancer therapeutics market are Amgen Inc., AstraZeneca Plc., Bayer AG, Bristo-Myers Squibb Company, Pfizer Inc., etc.

Which is the most leading region in the Cancer Therapeutics Market?

North America tops the global cancer therapeutics market accounting for 41.3% of global market share in 2022.

Which end-user segment contributes maximum share in Cancer Therapeutics sales?

Cancer and radiation therapy segment under the end-user segment contributes 43.4% of market share in global sales of cancer therapeutics.

Cancer Therapeutics Market

Schedule a Call